Delivery Order SPE2DB25D3201-SPE2DB26FNNXV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of OxyContin ER 40 mg tablets (100-count packages) valued at $1,322.76. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of October 29, 2025. The order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and constitutes a child contract under the company's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $2,370.38 delivery order contract on September 18, 2025, for the supply of OxyContin ER 20 mg tablets (100-count units). The contract is structured as a firm fixed-price delivery order with a completion date of September 19, 2025, and represents a non-set-aside competitive award. The awardee will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 5, 2025, for the supply of OxyContin ER 10 mg tablets (100-count units) with a contract ceiling value of $1,824.59. This is a firm fixed-price delivery order with an ultimate completion date of May 6, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain, awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of OxyContin ER 80 mg tablets (100-count units) valued at $1,796.20. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, representing a single-transaction purchase of pharmaceutical inventory. The contract was competitively awarded without set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of OxyContin ER 20 mg tablets in quantities of 100 per unit, with a ceiling value of $1,867.65. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of OxyContin ER 20 mg tablets in quantities of 100 units. The contract is valued at $3,667.68 with a firm fixed-price structure and is scheduled for completion by August 6, 2025. This competitively awarded delivery order carries no set-aside designation and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of OxyContin ER 40 mg tablets (100-count units) with a contract ceiling value of $8,112.79. This non-competitive, firm fixed-price delivery order is scheduled for completion by November 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of OxyContin ER 30 mg tablets (100 count) with a contract value of $7,759.02. This is a firm fixed price delivery order with an ultimate completion date of September 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical supply will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,845.42 on August 5, 2025, for the supply of OxyContin ER 20 mg tablets (100-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 6, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order was issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of OxyContin ER 10 mg tablets (100-count) valued at $3,143.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 7, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB26FNNXVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of OxyContin ER 20 mg tablets (100-count units) with a contract ceiling value of $1,490.43. This competitively awarded delivery order employs firm fixed pricing with an ultimate completion date of November 10, 2025. The contract is issued without a set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. The prime IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare systems globally. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen fulfills medical procurement requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems. The company's federal contract portfolio demonstrates consistent capability to meet DoD pharmaceutical supply needs through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 11/7/25 |